AllianceBernstein’s Ginkgo Bioworks DNA Stock Holding History

AllianceBernstein’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$342K	Buy	55,792 +32,700	+142%	+$273K	﹤0.01%	2922
2026 Q1	$192K	Hold	23,092	–	–	﹤0.01%	3059
2025 Q4	$192K	Hold	23,092	–	–	﹤0.01%	3077
2025 Q3	$337K	Sell	23,092 -5,090	-18%	-$60.9K	﹤0.01%	2890
2025 Q2	$317K	Buy	+28,182	New	+$218K	﹤0.01%	2887
2024 Q3	–	Sell	-2,032	Closed	-$27.2K	–	3242
2024 Q2	$27.2K	Sell	2,032 -9,467	-82%	-$282K	﹤0.01%	3217
2024 Q1	$534K	Buy	11,499 +56	+0.5%	+$2.9K	﹤0.01%	2561
2023 Q4	$774K	Buy	11,443 +1,250	+12%	+$76.5K	﹤0.01%	2399
2023 Q3	$738K	Sell	10,193 -82	-0.8%	-$6.56K	﹤0.01%	2377
2023 Q2	$764K	Buy	10,275 +4,631	+82%	+$274K	﹤0.01%	2421
2023 Q1	$300K	Sell	5,644 -255	-4%	-$16.2K	﹤0.01%	2771
2022 Q4	$399K	Buy	5,899 +925	+19%	+$85.1K	﹤0.01%	2748
2022 Q3	$621K	Sell	4,974 -47	-0.9%	-$5.6K	﹤0.01%	2542
2022 Q2	$478K	Buy	+5,021	New	+$612K	﹤0.01%	2704

Other funds holding DNA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

AllianceBernstein's DNA Position: Q2 2026 in Review

AllianceBernstein increased its Ginkgo Bioworks (DNA) stake by 142% in Q2 2026, buying an estimated $273K and bringing the position to 55,792 shares worth $342K. The position accounts for ﹤0.01% of the portfolio, ranked #2922.

AllianceBernstein first reported a position in DNA in Q2 2022 and has held it in 14 quarters since. The position peaked at $774K in Q4 2023. 184 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

AllianceBernstein held 55,792 shares of Ginkgo Bioworks worth $342K as of Q2 2026.
AllianceBernstein bought 32,700 Ginkgo Bioworks shares in Q2 2026, an estimated $273K.
Ginkgo Bioworks made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #2922 holding.
AllianceBernstein first reported a position in Ginkgo Bioworks in Q2 2022 and has held it in 14 quarters since.
AllianceBernstein's Ginkgo Bioworks position peaked at $774K in Q4 2023.
184 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.